Tags : Celyad

Celyad Signs an Exclusive License Agreement with Horizon Discovery for

 Shots: Celyad to get hold of Horizon’s shRNA technology for generation and development of allogenic CAR-T therapies shRNA (Short hairpin) technology is based on DNA and contains a selectable marker to allow elimination of cells that didn’t transfected or transduced Celyad’s novel CYAD-101 is a non-gene-edited allogeneic CAR-t candidate, NKG2D-based is developed by using the […]Read More

Celyad Announces Successful Dosing of CYAD-01 IV in P-I THINK

Shots: The P-I THINK ongoing trial is assessing CYAD-01 in mCRC patients administering cyclophosphamide (300 mg/m²) and fludarabine (30 mg/m²), evaluating its safety and ATR CYAD-01 investigational CAR-T therapy with expressing NKG2D receptor of NK cells, administration has shown no toxicity till date in its first enrolled patient in THINK trial   CYAD-01 is under clinical […]Read More